Analytical Data
-
Gene name
RRAS2
- Application
-
Alternative Names
Ras-like protein TC21 Teratocarcinoma oncogene
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P62070
-
Expression Region
1-204aa
-
Molecular Weight
50.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RRAS2, a member of the RAS superfamily of small GTPases, plays a crucial role in various cellular processes, including cell proliferation, differentiation, and survival. It is known to be involved in signaling pathways that regulate cytoskeletal dynamics and gene expression, making it significant in cancer biology and other diseases. The understanding of RRAS2's function has been muddied by the complexity of RAS-mediated signaling networks. Researchers have increasingly focused on characterizing RRAS2 as a potential therapeutic target, especially in cancers where its expression or activity is dysregulated. The production of recombinant RRAS2 protein through various expression systems enables in-depth studies of its biochemical properties, interaction partners, and functional implications in signaling pathways. By examining the protein's role in oncogenesis and other cellular contexts, scientists aim to elucidate its potential as a biomarker or therapeutic target. Current efforts include investigating RRAS2's structural characteristics and its interactions with small molecules, which could pave the way for novel treatment strategies in RRAS2-associated malignancies. Overall, the study of RRAS2 recombinant protein is not only pivotal for advancing basic research in cell signaling but also holds promise for translational applications in cancer therapy.
